Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Open Access
- 1 October 2010
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 5 (10) , 1644-1648
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2009
- Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality TherapyJournal of Clinical Oncology, 2007
- Current Status of Second-Line Treatment and Novel Therapies for Small Cell Lung CancerJournal of Thoracic Oncology, 2007
- Amrubicin for non-small-cell lung cancer and small-cell lung cancerInvestigational New Drugs, 2007
- Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice GuidelineJournal of Thoracic Oncology, 2007
- Phase II Trial of Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Trial 1597Journal of Clinical Oncology, 2003
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000